Europe in the fourth quarter of 2016. Achieving these milestones positions us to potentially bring duvelisib to patients next year, stated Adelene Perkins, president and chief executive officer. Infinity is also advancing several clinical studies designed to evaluate the safety and activity of du
Date: Jun 15, 2016
Category: Business
Source: Google
Infinity Closes Research Ops as Blood Cancer Drug Comes Up Short
CEO Adelene Perkins (pictured, left) said in a statement that Infinity was hoping for a larger clinical benefit. RBC Capital Markets analyst Michael Yee called the data disappointing in a research note, adding that the results dont stand up to a rival marketed drug from Gilead Sciences (NASDAQ:
Date: Jun 14, 2016
Category: Business
Source: Google
Infinity Pharma (INFI) Announces Duvelisib Phase 2 Met Primary Endpoint in r/r NHL; Will Undertake Restructuring
"While the DYNAMO study met its primary endpoint, we hoped that treatment with duvelisib as a monotherapy would have provided a larger clinical benefit for patients with advanced indolent non-Hodgkin lymphoma, a difficult-to-treat disease," stated Adelene Perkins, president and chief executive offic"This restructuring is a necessary step to preserve financial resources as we explore options for duvelisib and the advancement of IPI-549, our second clinical program," stated Adelene Perkins, president and chief executive officer. "These were very difficult decisions that were undertaken, and I wo
This collaboration is an important step toward fulfilling Infinitys objective of bringing better treatments to patients, Adelene Perkins, president and CEO of Infinity, said in a statement. AbbVie will be a wonderful partner for Infinity, bringing all of the expertise and scale of a successful,